Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Retained Earnings (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Retained Earnings for 6 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.0% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30000.0 through Dec 2025, up 100.0% year-over-year, with the annual reading at $30000.0 for FY2025, 100.0% up from the prior year.
  • Retained Earnings for Q4 2025 was $30000.0 at Lexicon Pharmaceuticals, up from $29000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $30000.0 in Q4 2025, with the low at -$2.0 billion in Q1 2025.
  • Average Retained Earnings over 3 years is -$1.2 billion, with a median of -$1.7 billion recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 1710940.71% in 2024, then soared 100.0% in 2025.
  • Over 3 years, Retained Earnings stood at -$1.8 billion in 2023, then decreased by 11.34% to -$2.0 billion in 2024, then skyrocketed by 100.0% to $30000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $30000.0, $29000.0, and -$14000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.